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Abstract: Raynaud’s phenomenon is a common condition characterized by vasospasm of the 
digital arteries and resulting cyanosis and redness. It often does not require pharmacologic 
management, but in some cases symptoms are severe and pharmacologic management is 
necessary. Calcium channel blockers are often used first-line, but in some patients are ineffective. 
Patients with severe symptoms or intolerance to available therapies have prompted explora-
tion of alternative therapies, including endothelin antagonists, phosphodiesterase-5 inhibitors, 
antioxidants, newer vasodilators, statins, and botulinum toxin. These newer therapies provide 
the focus for this review.
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Raynaud’s phenomenon (RP) is the transient digital ischemia that occurs upon 
exposure to cold temperature or emotional distress. It most commonly affects the 
fingers. RP occurs as a result of vasoconstriction of the digital arteries, precapillary 
arterioles, and cutaneous arteriovenous shunts.1 The initial white phase is marked by 
demarcated pale skin caused by vasoconstriction and cessation of regional blood flow. 
The second phase is a cyanotic phase as the residual blood in the finger desaturates. 
The attack usually ends with rapid reflow of blood to the digits, which results in a 
red appearance of the digits. The attack is often accompanied by pain or paresthesia 
due to sensory nerve ischemia. The prevalence of RP in the general population is 
approximately 3 to 5 percent.1,2
Primary RP is characterized by symmetric attacks; the absence of tissue necrosis, 
ulceration, or gangrene; the absence of a secondary cause; normal nailfold capillaries; 
a negative test for antinuclear antibody; and a normal erythrocyte sedimentation 
rate. Symptoms are generally mild, and age of onset is generally younger than 
30 years.1,3
In contrast with primary RP, a secondary cause is suggested by age of onset 
greater than 30 years; episodes that are intense, painful, asymmetric, or associated 
with ischemic skin lesions; concomitant symptoms suggestive of a connective tissue 
disease; specific autoantibodies; and evidence of microvascular disease on micros-
copy of nail-fold capillaries.1,3 Up to 90% of patients with systemic sclerosis have 
secondary RP.4
Over 140 years since its first description, the pathophysiology of RP remains 
incompletely understood and is likely multifactorial. Vascular, intravascular, and neural 
abnormalities have all been implicated in the pathophysiology of RP. Among vascular Vascular Health and Risk Management 2010:6 168
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mediators, nitric oxide, endothelin-1, serotonin, thromboxane, 
and angiotensin have been suggested to play a role. Numerous 
neural mediators, including calcitonin gene-related peptide 
and neuropeptide Y, and agents interacting with alpha-adr-
enoreceptors have also been implicated through impairment 
of vasodilation and increased vasoconstriction. In addition, 
platelet activation, fibrinolysis, and oxidative stress may 
contribute.2,3
Nonpharmacologic therapies include avoidance of cold 
temperatures, emotional stress, caffeine, and smoking, as 
well as avoidance of vasoconstrictive medications.3,5 Phar-
macologic therapy has historically included dihydropyridine 
calcium channel blockers, alpha1-adrenergic blockers, 
angiotensin II receptor antagonists, topical nitroglycerin, 
and pentoxifylline.3,5 Patients with primary RP only occa-
sionally require pharmacologic therapy; while such therapy 
is more common in patients with secondary RP. Despite 
therapy, some patients with severe attacks will develop 
intense pain, ulceration and ischemic skin lesions, and 
gangrene, and may ultimately require therapy with intra-
venous prostaglandins. Patients with severe symptoms or 
intolerance to available therapies have prompted exploration 
of alternative therapies, including endothelin antagonists, 
phosphodiesterase type 5 (PDE5) inhibitors, antioxidants, 
and newer vasodilators. No guidelines have been published 
for the therapy of RP, and many of the agents used in the 
treatment of RP are used off-label.
Historical treatments and newer 
variations
Calcium channel blockers remain the most widely used class 
of drugs in the management of RP.3 The dihydropyridine cal-
cium channel blockers are most effective; nifedipine has been 
the most extensively studied. In a meta-analysis in primary 
RP, calcium channel blockers reduced frequency of attacks 
by 2.8 to 5 fewer attacks per week and severity by 33%.6 In 
another meta-analysis in RP secondary to systemic sclerosis, 
calcium channel blockers reduced RP attack frequency by 8.3 
attacks over 2 weeks and severity by 35%.7 Calcium chan-
nel blockers typically used include nifedipine, nicardipine, 
felodipine, and amlodipine; once daily and sustained release 
dosage forms are preferred.3
A recent Cochrane review identified no other oral vasodi-
lators with established efficacy in primary RP.8 Studies with 
angiotensin converting enzyme (ACE) inhibitors have not dem-
onstrated a clear benefit. The angiotensin II receptor antagonist 
losartan reduced the severity and frequency of RP to a greater 
extent than nifedipine in primary RP in one small comparative 
study.9 The alpha1-adrenergic blocker prazosin was found to be 
modestly effective in the treatment of RP secondary to sclero-
derma in another Cochrane review.10 The vasodilator fasudil, a 
rho-kinase inhibitor, is also undergoing evaluation for the treat-
ment of RP in patients with systemic scleroderma.11
Nitroglycerin ointments, sublingual tablets, and trans-
dermal patches have also been used in the therapy of RP, 
demonstrating improvements in finger temperature and 
perfusion, but with a high incidence of side effects including 
headache and dizziness. Topical nitroglycerin reduces the 
severity and frequency of vasospastic episodes in primary 
and secondary RP.12–14
A new formulation of topical nitroglycerin is currently 
undergoing evaluation in clinical trials and has been submit-
ted for approval in the United States. MQX-503 (MediQuest 
Therapeutics, Inc., Bothell, Washington, USA) consists of 
nitroglycerin in a microemulsion of approximately 50% 
lecithin-based organic phase and 50% water phase. It is 
rapidly absorbed, and has a rapid onset of action. MQX-503 
0.5% and 1.25% were compared with placebo gel applied to 
fingers immediately prior to a cold challenge in 36 patients 
with primary or secondary Raynaud. Improvements in blood 
flow as assessed by laser Doppler were observed as early as 
5 minutes after the cold challenge. The mean time to achieve 
baseline blood flow was shorter with MQX 1.25% applica-
tion; although there was no difference in time to achieve 50% 
or 70% baseline skin temperature or in pain/numbness/tin-
gling scores between the 3 groups.15
MQX-503 reduced the severity of RP, but not the dura-
tion or frequency, in a randomized, double-blind, placebo-
controlled study enrolling 219 patients with primary or 
secondary RP who experienced at least 5 RP episodes in a 
7-day period during a placebo run-in phase. Over 90% of 
patients were female, with a mean age of 46 years. Over two-
thirds had secondary RP, primarily associated with systemic 
sclerosis. Patients received MQX-503 0.9% or placebo with 
instructions to apply gel to the affected finger immediately 
before or up to 5 minutes after the onset of a RP event. The 
change in mean daily Raynaud’s Condition Score (RCS) from 
baseline, the primary endpoint, was 0.48 with MQX-503 
(14.3%) compared with 0.04 (1.3%) with placebo (P  0.04). 
The mean number and duration of RP events did not differ 
between treatments. In patients with systemic sclerosis, new 
digital ulcers developed with similar frequency in the two 
groups (9% with MQX-503 and 13% with placebo; P = 0.51). 
Adverse effects did not differ between groups; headache 
occurred in 23% of MQX-503 treated patients and 21% of 
placebo recipients.16Vascular Health and Risk Management 2010:6 169
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In a randomized, double-blind, crossover study enrolling 
109 patients with moderate to severe primary or secondary 
RP (mean baseline RCS 3.9), treatment with MQX-503 
0.9% applied immediately before or within 5 minutes of 
onset of an attack was associated with a lower mean RCS 
than placebo (2.92 vs 3.17; P = 0.009). An improvement in 
RCS of at least 2 points was achieved in 42% of patients 
with MQX-503 compared with 23% of patients with placebo. 
Mean measures of pain and numbness were also lower with 
MQX-503 compared with placebo.17
In combined data from three phase 3 studies of MQX-503 
assessed for safety and tolerability, adverse events occurred 
with similar frequency with MQX-503 and vehicle placebo: 
headache (17% and 15%), dizziness (6% and 5%), and skin 
irritation (2% and 2%).18
Prostaglandin analogs
For patients with an insufficient response to traditional 
vasodilators, prostaglandin analogs are sometimes given. 
Most of the literature involves the investigational use of 
iloprost, a stable analog of epoprostenol (prostaglandin I2), 
which has demonstrated variable activity in RP associated 
with systemic sclerosis. Iloprost is a potent vasodilator 
and inhibitor of platelet aggregation. In a 1998 Cochrane 
review, intravenous iloprost was reported to be effective in 
the treatment of RP secondary to scleroderma – decreasing 
the frequency and severity of attacks and preventing or heal-
ing digital ulcers.19 Results have not been consistent across 
all studies though. Intermittent iloprost infusions reduced 
the frequency and severity of RP attacks in patients with 
RP secondary to systemic sclerosis in a large randomized, 
placebo-controlled, double-blind study; however, there was 
no difference between treatments in digital ulcer healing.20 
Iloprost was also associated with reduced frequency and 
severity of attacks in two small crossover studies.21,22 In 
another small study also enrolling patients with systemic 
sclerosis iloprost had no effect on RP severity or frequency, 
but was associated with improved ulcer healing.23 In another 
small study improvement in the frequency of RP attacks was 
observed, with no difference in duration or severity.24 High 
and low dose regimens were associated with a reduction in 
frequency, severity, and duration of RP attacks in a double-
blind study and in an open-label study. A reduction in digital 
ulcers was also reported in the latter.25,26 Other small studies 
compared intravenous iloprost with nifedipine in patients 
with RP associated with systemic sclerosis. Short term 
intravenous iloprost infusions produced a reduction in the 
number, duration, and severity of RP attacks comparable to 
oral nifedipine.27 Intermittent iloprost infusions improved 
skin scores and RP severity scores to a greater extent than 
oral nifedipine in a long-term comparative study.28 Table 1 
summarizes the key studies with the intravenous iloprost. 
Other case reports, case series and observational studies 
have also described reduced RP attack severity, duration, 
and frequency, and improved ulcer healing with intermittent 
iloprost infusions.29–34 Iloprost was associated with a high 
incidence of adverse reactions during infusion, including 
headache, flushing, nausea, jaw pain, diarrhea, vomiting, 
injection site reactions, and myalgia; however, intermittent 
administration is possible.20,22,23,28
Other studies have also assessed an investigational oral 
iloprost in patients with RP secondary to systemic sclerosis, 
again with variable results. In one large study, oral iloprost 
50 mcg twice daily for 6 weeks was no more effective than 
placebo in reducing the frequency, duration, or severity of 
RP attacks.35 In a smaller study, oral iloprost 150 mcg twice 
daily for 10 days was also no more effective than placebo in 
reducing RP attack duration or severity, was but preferred 
by patients.36 In another smaller study, oral iloprost 50 mcg 
and 100 mcg twice daily for 6 weeks was associated with 
reduced RP attack duration and severity, but no change in 
frequency.37 Reduced duration and severity of RP attacks 
was also reported in a series of 20 patients with primary or 
secondary RP treated with inhaled iloprost.38
Other prostaglandin analogs have also been assessed, 
without demonstrating consistent benefit. In a small open-
label assessment, daily infusion of alprostadil for six days 
was associated with a reduced frequency and severity of RP 
attacks in patients with systemic sclerosis;39 however, in a 
double-blind, placebo-controlled study enrolling patients 
with primary RP or RP secondary to systemic sclerosis, IV 
alprostadil was no more effective than placebo.40 A double-
blind study revealed no differences between oral beraprost 
and placebo in the treatment of primary RP.41
Endothelin receptor antagonists
More recently studies have assessed the use of oral endothelin 
receptor antagonists as an alternative to prostaglandins in 
patients with severe RP not responding to other therapies. 
Endothelin-A (ETA) receptors are found primarily in vascu-
lar smooth muscle cells and mediate vasoconstriction and 
cell proliferation. Endothelin-B (ETB) receptors are found 
primarily on endothelial cells and mediate vasodilatation via 
nitric oxide. Bosentan acts as an antagonist primarily at ETA 
receptors, reducing vasoconstriction mediated by endogenous 
endothelin. In the United Kingdon and Ireland, bosentan is Vascular Health and Risk Management 2010:6 170
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approved for the prevention of new digital ulcers in patients 
with systemic sclerosis and digital ulcers. Approval was based 
on the results of two studies (Table 2).
One randomized, double-blind, placebo-controlled study 
enrolling 122 patients with systemic sclerosis assessed the 
effects of bosentan in the prevention of digital ulcers. Patients 
received bosentan 62.5 mg twice daily for 4 weeks, then 
125 mg twice daily for 12 weeks, or placebo for 16 weeks. 
Bosentan-treated patients had a 48% reduction in the mean 
number of new ulcers compared with those in the placebo 
group (1.4 vs 2.7 new ulcers; P = 0.0083). A similar percent-
age of patients in both groups developed ulcers, and bosentan 
did not appear to delay development of the first digital ulcer. 
There was no difference between treatment groups in the 
healing of existing ulcers.42 In an open-label extension of 
this study, 88 patients (57 previously in the bosentan arm and 
31 previously in the placebo arm) continued bosentan therapy 
for an additional 12 weeks. The mean number of new ulcers 
during follow-up was 0.7.43 In another similar study enrolling 
188 patients with systemic sclerosis, bosentan 62.5 mg twice 
daily for 4 weeks and then 125 mg twice daily for 20 to 
32 weeks was compared with placebo in the prevention and 
healing of digital ulcers. Total new ulcers during 24 weeks of 
follow-up were 1.9 on bosentan vs 2.7 on placebo (P = 0.035). 
Healing parameters, including time to healing of a selected 
cardinal ulcer, to to healing of all digital ulcers, and percent 
of patients with complete healing did not differ between 
treatment groups.44 Another study noted improvement in 
flow-mediated dilation with bosentan therapy in patients 
with systemic sclerosis, but did not include assessment of 
the frequency or severity of RP or digital ulcers.45
The use of bosentan in the treatment of digital ulcers in 
26 patients with systemic sclerosis unresponsive to CCB, 
ARBs, and sildenafil has also been described. Bosentan 
62.5 mg twice daily for the first month, then 125 mg twice 
daily for an additional 35 weeks was administered. Healing 
Table 1 Summary of intravenous iloprost clinical trials on Raynaud’s phenomenon (RP)
Patients Study design Active treatment Outcomes References
131 patients  
secondary RP
Randomized  
double-blind  
placebo-controlled
iloprost 0.5–2 ng/kg/min iV infusion  
over 6 hours on 5 consecutive days
Frequency and severity reduced
Physician’s rating of treatment effect improved 
No difference in digital ulcer healing
20
35 patients  
secondary RP
Randomized  
double-blind  
placebo-controlled
iloprost 0.5–2 ng/kg/min over 6 h  
on 5 consecutive days
Complete digital ulcer healing  
with iloprost
No difference in  
frequency, duration, and severity
23
13 patients  
secondary RP
Randomized  
double-blind  
placebo-controlled  
crossover
iloprost 0.5–2 ng/kg/min  
over 6 h on 5 consecutive days
Frequency reduced  
No differences in duration  
or severity
24
29 patients 
26 secondary RP  
3 primary RP
Randomized  
Double-blind  
placebo-controlled  
crossover
iloprost 0.5–2 ng/kg/min over 6 h  
on 3 consecutive days
Frequency and severity reduced  
No difference in duration
22
12 patients  
secondary RP
Randomized  
double-blind  
placebo-controlled  
crossover
iloprost 1–3 ng/kg/min over  
5 hours on 3 consecutive days
Frequency and severity  
decreased with iloprost
21
55 patients  
secondary RP
Randomized  
double-blind
iloprost 0.5 ng/kg/min or  
iloprost 2 ng/kg/min over 6 h  
on 3 consecutive days
Frequency, severity, duration, and  
digital skin lesions reduced to similar  
extent with low dose and high dose
25
46 patients  
secondary RP
Randomized  
single-blind
iloprost 2 ng/kg/min over 8 h on  
5 consecutive days, then over  
8 hrs on 1 day every 6 weeks or  
Nifedipine 40 mg/day
Skin scores reduced to greater extent  
with iloprost than nifedipine
Severity scores reduced with iloprost, but  
not with nifedipine
28
23 patients  
secondary RP
Randomized  
double-blind  
double-dummy
iloprost 0.5–2 ng/kg/min for  
8 hours on 3 consecutive days,  
repeated at week 8 or Nifedipine 10 mg 
3 times daily × 4 weeks, then 20 mg 3 times 
daily × 12 weeks
Frequency, duration, severity, and  
incidence of digital lesions reduced  
to comparable extent with iloprost  
and nifedipine
27Vascular Health and Risk Management 2010:6 171
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of ulcers was reported in 65% of patients after a median 
of 25 weeks (range 8 to 26 weeks).46 Reduction in ulcers, 
improved ulcer healing, and improvement in RP frequency 
and severity have also been reported in several case series and 
case reports including patients with systemic sclerosis.47–53 
while another case series observed no improvement in RP 
activity, microvascular blood flow, systolic finger pressures, 
or disability scores.54
Bosentan toxicities include serious liver injury and major 
birth defects. In the United States bosentan is only approved 
by the Food and Drug Administration for use in the treatment 
of pulmonary arterial hypertension and is only available 
through a limited distribution system.
Phosphodiesterase type 5 inhibitors
Nitric oxide vasodilates and inhibits platelet activation by 
generating cyclic guanosine 5′-monophosphate.55 cGMP is 
hydrolyzed by phosphodiesterases, particularly the cGMP-
specific phosphodiesterase-5 isoenzyme. Sildenafil, tadalafil, 
and vardenafil are selective inhibitors of cGMP-specific 
phosphodiesterase type 5 which increases cGMP, resulting in 
enhanced cGMP-dependent microvascular and macrovascu-
lar dilation.5,55 The use of PDE5 inhibitors is being explored 
in patients with RP because of their potential effects on the 
microvascular and macrovascular circulation.
Several small studies have assessed sildenafil, tadalafil, 
and vardenafil in the treatment of RP (study designs and 
key results are summarized in Table 3). These studies 
include a single-dose crossover study with sildenafil and 
alpha-tocopherol,56 a small study comparing tadalafil and 
pentoxifylline,57 two crossover studies comparing sildenafil 
and placebo,5,58 two crossover studies comparing tadalafil and 
placebo,59,60 and open-label uncontrolled studies of sildenafil, 
tadalafil, and vardenafil.61–64 Several of these studies have only 
been presented in meeting abstracts or as letters.56–62,64
A randomized, double-blind, crossover study compared 
the physiologic effects of single-dose sildenafil and alpha-
tocopherol in 15 patients with RP. Following sildenafil, basal 
forearm blood flow and plasma cGMP were increased, and 
systolic and diastolic blood pressure were reduced. Alpha-
tocopherol had no effect on any of these parameters.56 Clinical 
and blood flow effects of vardenafil have been assessed in 
40 patients with primary or secondary RP in an open-label 
pilot study. Laser-Doppler measurements revealed improved 
digital blood flow in 70% of patients. Among those respond-
ing, peripheral blood flow was increased at room temperature 
and in a cold-exposure test at both 1 hour and 2 weeks after 
initiation of vardenafil. Symptomatic improvement was also 
observed, along with a reduction in the duration, frequency, 
and severity of attacks.63 Objective digital temperature 
responses following a mild cold challenge were observed 
in 3 of 5 patients treated with single dose of sildenafil in 
another open-label uncontrolled study. Subjective responses 
were also observed.64
Symptomatic improvement has been reported in several 
open-label studies. Primarily subjective endpoints were 
assessed in an open-label uncontrolled study of sildenafil in 
10 female patients. Sildenafil 25 mg 3 times daily for 6 weeks 
was initiated following 5 days of intravenous iloprost therapy. 
Six of 10 patients demonstrated symptomatic improvement 
and five experienced ulcer healing. Among the six demon-
strating clinical improvement, four showed an increase in 
finger skin temperature on thermography.61 Healing was also 
observed with sildenafil in an open-label study enrolling 
Table 2 Summary of bosentan clinical trials on Raynaud’s phenomenon (RP)
Patients Study design Treatment Outcomes References
122 patients  
secondary RP
Randomized  
double-blind  
placebo-controlled
Bosentan 62.5 mg  
twice daily × 4 weeks,  
then 125 mg twice  
daily × 12 weeks
Fewer new digital ulcers per patient with bosentan  
(primary study outcome; mean of 1.4 new ulcers  
per patient on bosentan vs 2.7 new ulcers per patient  
on placebo [P = 0.0083])
No difference in percentage  
of patients with new digital ulcers, time to first ulcer,  
ulcer healing, or functional improvement
42
188 patients  
secondary RP
Randomized  
double-blind  
placebo-controlled
Bosentan 62.5 mg  
twice daily × 4 weeks,  
then 125 mg twice  
daily × 20–32 weeks
Fewer new digital ulcers per patient with bosentan  
(primary study outcome; mean of 1.9 new ulcers  
per patient on bosentan vs 2.7 new ulcers per patient  
on placebo [P = 0.035])
No difference in time to healing  
of cardinal ulcer, time to healing of all digital ulcers,  
and percent with complete healing
44Vascular Health and Risk Management 2010:6 172
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19 patients with systemic scleroderma, severe Raynaud, and 
digital ulcers.65,66 Another open-label study assessed tadalafil 
in 12 patients with secondary Raynaud and painful digital 
ulcers or finger tip necrosis at baseline. The mean time to 
ulcer healing was 5 weeks and the mean time to healing of 
fingertip necrosis was 8 weeks.62 In addition to open-label 
studies, several case reports and case series describing the 
use of PDE5 inhibitors in patients primarily with secondary 
RP have reported symptomatic improvement, ulcer healing, 
and objective improvements in blood flow.4,67–80
Tadalafil has been compared with pentoxifylline in the 
treatment of RP in a study enrolling 14 male patients with 
severe Raynaud associated with autoimmune diseases. RCS 
demonstrated greater improvement in the tadalafil treated 
patients. Attack frequency declined 59% with tadalafil treat-
ment compared with 36% reduction with pentoxifylline. 
Attack duration was also significantly reduced with tadalafil 
therapy compared with pentoxifylline. Both physician and 
patient assessments of RP were also improved after 4 weeks 
of therapy with tadalafil (P  0.05 compared with 2 weeks 
Table 3 Summary of phosphodiesterase type 5 inhibitor clinical trials on Raynaud’s phenomenon (RP) with clinical endpoints
Patients Study design Treatment Outcomes References
Sildenafil
20 patients  
16 secondary RP  
2 primary RP
Randomized  
double-blind crossover  
placebo-controlled
Sildenafil 50 mg  
twice daily × 4 weeks
Frequency and duration reduced  
RCS improved
5
20 patients  
primary RP
Randomized  
double-blind crossover  
Placebo-controlled
Sildenafil 50 mg  
twice daily × 2 weeks
No difference between  
sildenafil and placebo in blood  
flow, disability, pain, or RCS
58
19 patients  
secondary RP
Open-label Sildenafil 25 to 150 mg/day  
for up to 6 months
Mean number of ulcers reduced  
VAS scores for RP, pain, and activity  
were improved
65,66
10 patients  
secondary RP
Open-label Sildenafil 25 mg 3 time s  
daily × 6 weeks initiated  
following 5 days of  
iV iloprost therapy
Symptomatic improvement and ulcer  
healing in approximately half
61
Tadalafil
25 patients  
secondary RP
Randomized  
double-blind  
cross-over
Tadalafil 20 mg or  
placebo every other  
day × 6 weeks
Frequency and duration reduced  
Mean daily RCS improved  
More ulcers healed during tadalafil  
Fewer new finger tip ulcers  
developed during tadalafil  
Improvements with tadalafil on Patient Global 
Assessment, Physician Global Assessment, and 
impact on daily living on SSc HAQ
59
39 patients  
secondary RP
Randomized double-blind  
placebo-controlled  
cross-over
Tadalafil 20 mg daily × 4 weeks No significant differences from placebo in RCS 
or RP frequency or duration
60
14 patients  
secondary RP
Active-controlled Tadalafil 20 mg 2 to 3 times per 
week × 4 weeks (9 patients)  
or pentoxifylline 600 mg twice  
daily × 4 weeks  
(5 patients)
RCS improved with tadalafil compared  
with pentoxifylline  
Attack frequency and duration reduced with 
tadalafil
57
12 patients  
secondary RP
Open-label Tadalafil 10 or 20 mg every  
other day × 6 weeks
Ulcer healing observed 62
Vardenafil
40 patients 
33 secondary RP  
7 primary RP
Open-label Vardenafil 10 mg twice  
daily × 2 weeks
RCS reduced 63
Abbreviations and notes: RCS, Raynaud’s Condition Score (patient assessment of the extent to which they felt handicapped by Raynaud attacks daily based on frequency, 
total daily duration, and severity of attacks using a 10-point scale; 0 points, subject felt not handicapped by Raynaud attacks; 10 points, subject felt extremely handicapped); 
HAQ, Health Assessment Questionnaire.Vascular Health and Risk Management 2010:6 173
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and P  0.05 vs controls). Results after 4 weeks of therapy 
were better than after 2 weeks of therapy.57
In a well-designed, randomized, double-blind, placebo-
controlled, crossover study, sildenafil was assessed in the 
treatment of RP resistant to vasodilatory therapy.5 This 
assessment included 16 patients with secondary RP and 
2 patients with primary RP. Inclusion criteria were the regu-
lar occurrence of painful Raynaud attacks and resistance to 
therapy with at least two conventional vasodilators. Therapy 
prior to study entry included calcium channel blockers in 
94% of patients, nitroglycerin in 39%, pentoxifylline in 28%, 
ACE inhibitors in 22%, intravenous prostaglandins in 17%, 
and bosentan in 6%. All vasodilatory agents were discon-
tinued prior to study entry. Mean capillary flow velocity 
increased with sildenafil, but not placebo. In addition, attack 
frequency and duration were substantially reduced with 
sildenafil. In all six patients with chronic digital ulcerations, 
healing was observed during sildenafil treatment. In two 
patients, ulcerations completely cleared during sildenafil 
treatment, but reappeared or progressed upon discontinua-
tion of sildenafil therapy.
Responses with tadalafil were observed in a randomized, 
double-blind, crossover study enrolling 25 patients with 
secondary Raynaud. The daily frequency, duration, and RCS 
scores were improved during tadalafil therapy. In addition all 
preexisting fingertip ulcers healed during the tadalafil phase, 
and fewer ulcers developed during the tadalafil phase than 
during the placebo phase.59
In contrast with the benefits observed in the above stud-
ies and case reports, no benefit was observed in 20 patients 
with primary RP treated with sildenafil in a randomized, 
double-blind, crossover study. Patients received sildenafil 
50 mg twice daily or placebo for 2 weeks, followed by a 
1-week washout period, and administration of the alternate 
agent for 2 weeks; this dosage regimen was identical to the 
regimen used in the preceding sildenafil study. No differences 
between sildenafil and placebo was observed in frequency 
and duration of Raynaud attacks, or measurements of blood 
supply to the digits upon exposure to cold.58
Another randomized, double-blind, placebo-controlled 
study of tadalafil in 39 patients with secondary Raynaud 
revealed no significant differences from placebo in RCS, 
or frequency and duration of RP.60 Similarly, tadalafil did 
not improve digital blood flow or attenuate cold-induced 
vasoconstriction in a population of patients mostly with 
primary Raynaud.81
Limited adverse effect information was reported in these 
small studies and case reports. Adverse effects reported with 
sildenafil and vardenafil therapy in patients with RP have 
included headache, muscle pain, flushing, facial heat sensation, 
rhinorrhea, nausea, dyspepsia, dizziness, and visual abnormali-
ties.5,56,68 These adverse effects are similar to those observed 
with PDE5 inhibitors in the treatment of erectile dysfunction.
Serotonin receptor antagonists  
and serotonin reuptake inhibitors
The role of serotonin in the pathophysiology and management 
of RP is not clearly established. Remission of RP symptoms 
has been described in a patient treated with fluoxetine; 
possibly as a result of depletion of platelet serotonin.82 Other 
case reports have described improvement with sertraline 
and escitalopram83,84 A crossover study has also compared 
fluoxetine with nifedipine in the treatment of 26 patients 
with primary and 27 patients with secondary RP. Patients 
received fluoxetine 20 mg daily or nifedipine 40 mg daily 
for 6 weeks, followed by a 2-week washout period and then 
therapy with the alternate agent. Attack frequency and sever-
ity were reduced with either therapy; however, the effect was 
significant only during the fluoxetine therapy.85 Numerous 
other reports, however, have described exacerbation of RP 
symptoms following initiation of therapy with a serotonin 
reuptake inhibitors and serotonin partial agonists (fluoxetine, 
fluvoxamine, citalopram, reboxetine, tegaserod).86–90
Sarpogrelate is a selective serotonin 5HT2 receptor 
antagonist that is undergoing evaluation in the treatment 
of RP. In a small study enrolling 7 patients with systemic 
sclerosis, sarpogrelate 300 mg once daily for 12 months 
was associated with a decreased frequency and duration of 
RP, as well as the coldness, numbness and pain of RP. The 
effect appeared to be mediated by reduction in the plasma 
concentration of fibrinopeptide A (FPA), beta thromboglobu-
lin (beta-TG), and platelet factor 4 (PF4), and prevention of 
platelet aggregation.91 Improvement in the frequency and 
duration of RP and symptoms of coldness and pain were 
also described in a Japanese report including 32 patients with 
secondary RP treated with sarpogrelate 300 mg once daily for 
8 weeks, and in a meeting abstract reporting on 12 patients 
with secondary RP treated with sarpogrelate 300 mg once 
daily for 12 weeks.92,93
Antioxidants
N-Acetylcysteine has also demonstrated activity in patients 
with RP secondary to systemic sclerosis. The use of 
N-acetylcysteine in the treatment of RP has been described 
in an open-label pilot study enrolling 22 patients with RP 
secondary to systemic sclerosis. The study was conducted Vascular Health and Risk Management 2010:6 174
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over 11 weeks during the winter. Patients received a continu-
ous 5-day intravenous infusion of N-acetylcysteine starting 
with a 2-hour loading dose of 150 mg/kg followed by a dose 
of 15 mg/kg/hour. The primary outcome measures were the 
frequency and severity of RP attacks, and the number of 
digital ulcers. Frequency and severity of RP attacks were 
both reduced. Frequency was reduced from 21.2 RP attacks 
per week at baseline to 10.7 attacks per week from days 5 to 
19, 12.1 per week from days 20–33, and 14.1 per week from 
days 34 to 61. Severity scores declined from 5.5 at baseline 
to 3.4 at days 5 to 19, 2.9 at days 20 to 33, and 3.1 at days 
34 to 61. Digital ulcers were reduced at least 50% in 80% of 
patients at day 33 after the infusion, with 53% demonstrating 
complete ulcer healing. In a cold challenge test assessed by 
photoelectric plethysmography, mean recovery time fell by 
approximately 70%.94 In a subsequent assessment of the long-
term use of N-acetylcysteine in patients with RP secondary to 
systemic sclerosis, patients treated with an intravenous dose 
of 15 mg/kg/hour for 5 consecutive hours every 2 weeks from 
October to May for 2 years demonstrated increased global 
hand perfusion, reduced plasma adrenomedullin levels, and 
reduced frequency and severity of RP attacks. Frequency of 
RP declined from 23.2 per week at baseline to 13.2 per week 
after 2 weeks of treatment (43.1% decline) and to 10.8 per 
week during the last 4 weeks of follow-up (53.4% decline). 
RP severity scores declined approximately 40%. Adreno-
medullin is a potent vasodilator endothelial-derived peptide 
which levels increased in patients with systemic sclerosis. 
N-acetylcysteine seemed to act as a vasodilator, perhaps via 
modulation of adrenomedullin levels.95
Statins
The observed effects of the statins on endothelial function 
prompted assessment of statins in the therapy of RP associ-
ated with systemic sclerosis. One randomized study enrolled 
84 patients with RP secondary to systemic sclerosis despite 
ongoing vasodilator therapy. Patients received atorvastatin 
40 mg per day (56 patients) or placebo (28 patients) for 
4 months. The primary outcome was the number of digital 
ulcers, which declined from 3.3 at baseline to 2.4 at 4 months 
in the atorvastatin group compared with a reduction from 3.4 
at baseline to 3 at 4 months in the placebo group (P = 0.001). 
Patients in the atorvastatin group had a mean of 1.6 new 
ulcers compared with 2.5 new ulcers per patient in the pla-
cebo group (P = 0.003). Patients in the atorvastatin group 
also demonstrated improvement in the Scleroderma Health 
Assessment Questionnaire Disability Index (SHAQ-DI; 
P = 0.001), VAS for RP severity (P = 0.005), VAS for digital 
ulcer severity (P = 0.001), and VAS pain scales (P = 0.004) 
compared with the placebo group. Endothelial markers of 
activation that improved from baseline in the statin group 
compared with the placebo group included IL-6, TNF-alpha, 
ET-1, nitric oxide, thrombomodulin, soluble E-selectin, von 
Willebrand factor, monocyte chemoattractant, fibrinogen, 
high sensitivity C-reactive protein, erythrocyte sedimentation 
rate, lipid peroxide, and malonylaldehyde.96
Botulinum toxin-A
Decreased pain and numbness, decreased frequency of 
vasospastic attacks, healing of digital ulcers, and increased 
blood flow was observed in three case series and a case report 
assessing interdigital injections of botulinum toxin in patients 
with primary and secondary RP.97–100 A dual mechanism 
of action has been suggested: inhibition of vasospasm by 
blocking cold-induced vasoconstriction and by preventing 
recruitment of alpha2 receptors to vascular smooth muscle 
in cold conditions.98 Placebo-controlled studies are necessary 
to confirm the activity of botulinum toxin in RP.
Conclusion
In patients with primary RP, nonpharmacologic lifestyle 
modifications remain the first-line therapy. Calcium channel 
Table 4 Newer therapies with demonstrated efficacy in Raynaud’s phenomenon
Agents Class Route RP population Effect
MQX-503 Nitrate Topical Primary and secondary Reduced attack severity
iloprost Prostaglandin analog intravenous Secondary Reduced duration, frequency, and severity  
of attacks; improved ulcer healing
Bosentan endothelin receptor  
antagonist
Oral Secondary Reduced number of new digital ulcers
Sildenafil Phosphodiesterase  
type 5 inhibitor
Oral Secondary Reduced duration, frequency, and severity  
of attacks; improved ulcer healing
Tadalafil Phosphodiesterase  
type 5 inhibitor
Oral Secondary Reduced duration, frequency, and severity  
of attacks; improved ulcer healingVascular Health and Risk Management 2010:6 175
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blockers or topical nitrates may be considered for those without 
an adequate response to lifestyle modification. Other therapies 
have not been demonstrated to be effective in this population.
In patients with secondary RP, lifestyle modifications 
should also be applied; however, pharmacologic management 
is more likely to be necessary. In addition to calcium chan-
nel blockers, there may be a role for topical nitrates, PDE5 
inhibitors, endothelin antagonists, or prostaglandin derivatives 
(Table 4). Although additional clinical studies are necessary to 
validate the efficacy of these agents in RP, the clinical data, oral 
availability, and favorable tolerability profile suggests a trial of 
a PDE5 inhibitor may be appropriate in patients with severe 
symptoms associated with RP despite traditional vasodilator 
therapy. Further studies of statins, botulinum toxin, N-acetyl-
cysteine are necessary to establish the role of these agents.
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